Avalyn Pharma (NASDAQ:AVLN) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Avalyn Pharma (NASDAQ:AVLN) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently commented on AVLN. Raymond James Financial started coverage on Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price target for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a research report on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Price Performance

AVLN traded down $0.31 during trading on Friday, reaching $30.28. 574,889 shares of the stock traded hands, compared to its average volume of 480,376. The firm’s 50-day moving average price is $28.66. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. Avalyn Pharma has a fifty-two week low of $22.24 and a fifty-two week high of $40.17. The stock has a market cap of $1.34 billion and a PE ratio of -1.33.

Avalyn Pharma (NASDAQ:AVLN) last issued its earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). Research analysts anticipate that Avalyn Pharma will post -3.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Avalyn Pharma news, insider Fmr Llc sold 175,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00. Following the transaction, the insider directly owned 2,109,535 shares in the company, valued at $61,324,182.45. This trade represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Institutional Trading of Avalyn Pharma

Large investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in shares of Avalyn Pharma by 73.7% during the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock valued at $15,784,000 after acquiring an additional 235,009 shares during the last quarter. Profund Advisors LLC acquired a new stake in Avalyn Pharma in the 3rd quarter worth approximately $668,000. China Universal Asset Management Co. Ltd. acquired a new stake in Avalyn Pharma in the 3rd quarter worth approximately $29,000. Manchester Capital Management LLC bought a new stake in Avalyn Pharma during the third quarter worth approximately $36,000. Finally, Braidwell LP bought a new stake in Avalyn Pharma during the second quarter worth approximately $26,382,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.